nivolumab,ipilimumab,cabozantinib
bms
[' ipi ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo', 'cosmic-313']
 with updated cosmic-313 data. still pfs benefit with triplet but lose signal in imdc poor risk group despite similar toxicity/tolerance between poor and intermediate risk categories #gu23 
GU Oncologist at @UHhospitals